Property & Real Estate
Developers, REIT sponsors, integrated property groups. Concentrated controlling-shareholder positions and long-tenure family holdings dominate this sector.
Sectors we serve.
Coverage across the industries that anchor Hong Kong’s capital markets. Each transaction is structured with sensitivity to the specific dynamics of its sector.
Hong Kong’s listed universe is shaped by sectors that map closely to the structural strengths of the city as a financial centre: property, financials, technology, and the consumer economy at its core; healthcare, energy, industrials, and the new generation of biotech listings under Chapter 18A around it. We have structured against shareholdings in each.
Financials & Insurance
Banks, insurers, securities firms, asset managers. Substantial cross-holdings and strategic stakes; particular regulatory sensitivity.
Technology & Internet
HKEX-listed technology, platform, and software businesses; mainland China tech with HK secondary listings; founder concentrations.
Consumer & Retail
Branded consumer goods, luxury, F&B, retail chains. Family-led businesses and second-generation succession transactions.
Healthcare & Biotech
Hospitals, pharma, medical devices, and Chapter 18A pre-revenue biotech listings with sophisticated structuring requirements.
Energy & Resources
Conventional and renewable energy, materials, metals, and resources companies with HKEX primary or secondary listings.
Industrials & Manufacturing
Industrial groups, manufacturing, logistics, and infrastructure businesses across Greater China.
Conglomerates & Holding Cos
Multi-sector listed holding companies, family conglomerates, and investment holding vehicles.
02 · Sensitivity
Sector Matters
Why sector shapes structure.
A property holding, a tech founder’s stake, and a Chapter 18A biotech position have entirely different liquidity, volatility, and regulatory profiles. The structure of a transaction must respect these differences.
A REIT sponsor’s position trades with different dynamics than a recently-listed Main Board technology issuer. A founder’s stake in a Chapter 18A biotech, before revenue, requires materially different LTV and structural treatment than a holding in a long-listed financial institution. We do not apply a generic structure across sectors. Each transaction is structured against the specific dynamics of the underlying name.